Lupus Erythematosus, Systemic
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
DNase activity was decreased in iLN compared to SLE (20% had one-half DNase activity) despite similar serum levels of DNase1/DNase1L3.
|
31092713 |
2020 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Moreover, in 35 patients with drug-naïve SLE (n = 35), we investigated correlation between NETs-associated markers [DNase I concentration, myeloperoxidase (MPO) activity, anti-MPO antibodies, cell-free DNA (cfDNA), NETolytic activity] with serological parameters [anti-dsDNA antibodies, C3, C4 and B-cell activating factor (BAFF) levels] and disease activity measured by modified SLE Disease Activity Index (M-SLEDAI-2K).
|
31444555 |
2019 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Since there is currently no cure for SLE the protective role of DNase1 as demonstrated in our study remains of great therapeutic interest.
|
30758851 |
2019 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Most Dnase1 and Dnase2 family members are poorly characterized, yet their elimination can lead to a wide range of diseases, including lethal anemia, parakeratosis, cataracts and systemic lupus erythematosus.
|
28666955 |
2017 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Deoxyribonuclease I gene polymorphism and susceptibility to systemic lupus erythematosus.
|
26547219 |
2016 |
Lupus Erythematosus, Systemic
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Similarly a significant association was observed between DNase1 reduction activity and SLE (p = 0.0001).
|
24564745 |
2014 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Identification of the functional alleles of the nonsynonymous single-nucleotide polymorphisms potentially implicated in systemic lupus erythematosus in the human deoxyribonuclease I gene.
|
24819173 |
2014 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
DNAse I Q222R polymorphism is a potential genetic risk factor for SLE in South Indian Tamils.
|
23963431 |
2013 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to screen DNASE1 gene for mutations that may have an effect on susceptibility to develop SLE.
|
19863681 |
2010 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Immunofluorescence staining for Dnase1 was performed on kidney biopsies from (NZBxNZW)F1 mice as well as from human SLE patients and controls.
|
20856893 |
2010 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
The aim of our work was to evaluate the DNASE1 contribution in the genetic susceptibility of rheumatoid arthritis (RA, n = 151), Sjögren syndrome (SS, n = 55) and SLE (n = 34) in Tunisia.
|
19360410 |
2009 |
Lupus Erythematosus, Systemic
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
DNase I does not correlate with sFas or sFasL, whereas it correlates with T cell surface Fas expression that is higher in patients with active SLE than in healthy controls.
|
19181929 |
2009 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
In this review we highlight the current findings in the pathophysiology, genetics, and therapeutical role of DNase1 in SLE.
|
18486922 |
2008 |
Lupus Erythematosus, Systemic
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Its relationship with SLE susceptibility, serum DNase I activity, anti-ribonucleoprotein (RNP), anti-double-stranded DNA (dsDNA), anti-nucleosome and anti-single-stranded DNA (ssDNA) antibodies was determined.
|
16449364 |
2006 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Systemic lupus-erythematosus: deoxyribonuclease 1 in necrotic chromatin disposal.
|
16352456 |
2006 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Genetic associations of polymorphisms in DNase I with the risk of SLE and the production of common autoantibodies were examined in a Korean population (350 SLE patients and 330 controls).
|
15333586 |
2004 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to genotype the single nucleotide polymorphisms (SNPs) of DNase1 and characterize its gene expression and alternatively spliced transcripts in Chinese patients with SLE in order to understand the pathogenic role of DNase1 in human SLE.
|
15569484 |
2004 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
The A/T mutation in exon 2 of the DNASE1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects.
|
14613299 |
2003 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Mice whose DNase 1 gene is knocked out are known to develop lupus and to be otherwise normal.
|
12708782 |
2003 |
Lupus Erythematosus, Systemic
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Thus, here we review current findings about the association of the defective clearance of autoantigens and SLE, focusing on mutations in the DNase I locus and their relationship to SLE.
|
12595613 |
2003 |
Lupus Erythematosus, Systemic
|
0.900 |
SusceptibilityMutation
|
disease |
ORPHANET |
These data are consistent with the hypothesis that a direct connection exists between low activity of DNASE1 and progression of human SLE.
|
11479590 |
2001 |
Lupus Erythematosus, Systemic
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
These data are consistent with the hypothesis that a direct connection exists between low activity of DNASE1 and progression of human SLE.
|
11479590 |
2001 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that lack or reduction of Dnase1 is a critical factor in the initiation of human SLE.
|
10835632 |
2000 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
MGD |
Our findings suggest that lack or reduction of Dnase1 is a critical factor in the initiation of human SLE.
|
10835632 |
2000 |
Lupus Erythematosus, Systemic
|
0.900 |
Biomarker
|
disease |
CTD_human |
|
|
|